I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| enterocyte | 4 studies | 28% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| enterocyte | 4 studies | 28% ± 5% |
Insufficient scRNA-seq data for expression of MEP1B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| intestine | 86% | 1638.57 | 832 / 966 | 25% | 2.64 | 131 / 527 |
| liver | 94% | 23.51 | 213 / 226 | 11% | 0.46 | 43 / 406 |
| stomach | 60% | 3.85 | 216 / 359 | 22% | 0.99 | 62 / 286 |
| lung | 77% | 5.41 | 446 / 578 | 5% | 0.32 | 54 / 1155 |
| uterus | 81% | 4.72 | 137 / 170 | 1% | 0.02 | 4 / 459 |
| spleen | 81% | 5.47 | 196 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 66% | 2.98 | 216 / 328 | 15% | 3.77 | 26 / 178 |
| skin | 79% | 5.24 | 1435 / 1809 | 0% | 0 | 0 / 472 |
| bladder | 71% | 3.24 | 15 / 21 | 7% | 0.19 | 33 / 504 |
| ovary | 75% | 4.61 | 135 / 180 | 1% | 0.05 | 5 / 430 |
| esophagus | 62% | 4.49 | 894 / 1445 | 13% | 0.48 | 23 / 183 |
| peripheral blood | 74% | 3.88 | 683 / 929 | 0% | 0 | 0 / 0 |
| adipose | 72% | 3.94 | 869 / 1204 | 0% | 0 | 0 / 0 |
| breast | 70% | 4.85 | 322 / 459 | 1% | 0.03 | 8 / 1118 |
| prostate | 70% | 3.58 | 171 / 245 | 0% | 0.00 | 2 / 502 |
| brain | 70% | 5.90 | 1848 / 2642 | 0% | 0.00 | 1 / 705 |
| blood vessel | 68% | 3.27 | 903 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 64% | 2.90 | 421 / 653 | 0% | 0 | 0 / 605 |
| kidney | 57% | 2.63 | 51 / 89 | 1% | 0.03 | 5 / 901 |
| adrenal gland | 57% | 2.14 | 146 / 258 | 0% | 0.01 | 1 / 230 |
| heart | 53% | 2.16 | 455 / 861 | 0% | 0 | 0 / 0 |
| muscle | 44% | 1.64 | 356 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006954 | Biological process | inflammatory response |
| GO_0006508 | Biological process | proteolysis |
| GO_0017090 | Cellular component | meprin A complex |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004222 | Molecular function | metalloendopeptidase activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | MEP1B |
| Protein name | Meprin A subunit (EC 3.4.24.-) (Endopeptidase-2) Meprin A subunit beta (EC 3.4.24.63) (Endopeptidase-2) (Meprin B) (N-benzoyl-L-tyrosyl-P-amino-benzoic acid hydrolase subunit beta) (PABA peptide hydrolase) (PPH beta) |
| Synonyms | hCG_25081 |
| Description | FUNCTION: Membrane metallopeptidase that sheds many membrane-bound proteins. Exhibits a strong preference for acidic amino acids at the P1' position. Known substrates include: FGF19, VGFA, IL1B, IL18, procollagen I and III, E-cadherin, KLK7, gastrin, ADAM10, tenascin-C. The presence of several pro-inflammatory cytokine among substrates implicate MEP1B in inflammation. It is also involved in tissue remodeling due to its capability to degrade extracellular matrix components. . |
| Accessions | J3QKX5 ENST00000581447.1 ENST00000269202.11 Q16820 |
